Strategic Regulatory Consulting & Planning

Applying experience, knowledge, and insights to plan and implement regulatory strategies for successful interactions with the FDA, MHRA, EMA, and other Global Regulatory Agencies.

Preparing your strategic regulatory plan for your development program starts before and continues after preparing your Investigational New Drug  (IND) application or Clinical Trial Application (CTA).  As you look to transition your compound into clinical trials, you need the right partner to guide your planning and decision-making.  Our regulatory, scientific, and communications experts provide strategic regulatory planning, cross-functional operational support, and the practical, real-world knowledge of how to present your regulatory strategy, non-clinical toxicology plans, clinical trial design, and product development goals to the regulatory agencies.


Regulatory Expertise Throughout the Entire Product Development Lifecycle


RegulatoryLifecycleChart_DarkGreenwithFade Background_Aug2021_ForPPT_USETHISONE


Regulatory Consulting for FDA & Global Regulatory Agencies

Our Regulatory experts provide regulatory guidance for product and program development through to the successful interactions with the FDA or other global regulatory agencies.  We focus on helping you with:

Strategic Program Planning

  • Develop the regulatory strategy and submission plan to support both US and global registrations
  • Explore the possibility of pursuing expedited or alternate regulatory pathways for faster approval, and writing the corresponding applications
  • Create non-clinical development plans
  • Assist in Contract Manufacturing Organization (CMO) selection, write and review full Chemistry, Manufacturing and Controls (CMC) sections for submissions (Module 3, Module 2.3), and perform overall gap analysis
  • Write and review the clinical development plans including trial design, sample size calculations, protocols, investigator brochures, electronic Case Report Forms (eCRFs), Statistical Analysis Plans (SAP) or Interim analysis plans (IAP)
  • Draft regulatory agency, board meeting, or investor presentations of the clinical development, CMC, regulatory and/or statistical plans
Veristat_icon_strategic consulting

Scientific-Minded Expertise

Veristat's Regulatory, statistical, medical/safety and communications experts prepared > 65 INDs/CTAs in the past year.

Overall Product Program Development

IND/CTA Writing, Gap Analysis, and Publishing

  • Protocol & Investigator Brochures
  • Administrative documentation (module 1)
  • General investigational plan
  • CMC Writing
  • Non-Clinical
  • Publishing of INDs and CTAs to regulatory agencies

Regulatory Agency Meeting Preparation & Support

Broad Range of Regulatory Consulting and Application Preparation Expertise

Our teams have prepared regulatory strategies, developed clinical program designs, and supported applications (INDs, NDAs, BLAs) for numerous programs to treat blood disorders, cancers, cardiovascular disease, endocrine disorders, genetic disorders, respiratory diseases, woman’s health issues and wound healing.

We will help you answer questions such as:

  • Am I ready to begin preparing my IND?
  • How many phase III studies do I need?
  • How many patients will I need overall?
  • When and how often do we need to meet with FDA?
  • Have we conducted enough toxicology studies to support entry into humans? 
  • Would my product qualify for the 505(b)(2) pathway?
  • What are the benefits of a special protocol assessment concurrence with FDA?
  • And, much more


Learn More with These Resources

Fact Sheet

Vaccines Fact Sheet

Vaccines have become an incredibly valuable way to prevent  the spread of lethal diseases around the world, making their development a priority. Veristat's commitment to improving ...



Rare Disease Infographic

Given the existence of over 7,000 rare diseases, Veristat works to support Rare Disease clinical trials from beginning to end.


Published Article

Pooled Analysis of the Phase 3 REVIVE Trials

With the growing numbers of bacterial infections becoming antibiotic-resistant, how do we treat infections that become extremely dangerous, cause abscesses, lesions, or ulcers that ...

Request A Proposal